Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age.
Phase of Trial: Phase I/II
Latest Information Update: 15 Sep 2015
At a glance
- Drugs Sunitinib (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 30 Jul 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 29 Jun 2012 Planned end date changed from 1 Apr 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 28 Apr 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2007-007553-31).